ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 199

Incremental Direct Medical Costs of Systemic Lupus Erythematosus Patients in the Years Preceding Diagnosis and the Impact of Sex: A General Population-Based Study

Natalie McCormick1,2, Carlo Marra3 and J. Antonio Avina-Zubieta4, 1Arthritis Research Canada, Richmond, BC, Canada, 2Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada, 3School of Pharmacy, University of Otago, Dunedin, New Zealand, 4Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: administrative databases, Economics, Health care cost, health disparities and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, November 5, 2017

Session Title: Health Services Research Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Little is known about the healthcare costs of systemic lupus erythematosus (SLE) patients in the years leading up to SLE diagnosis.  We estimated the incremental (extra) direct medical costs of a general population-based cohort of incident SLE for five years before diagnosis, and examined the impact of sex on these costs. 

Methods:

Data Source: Our administrative data captured all provincially-funded outpatient encounters and hospitalisations (1990-2013), and all dispensed medications, for ALL residents of the province of British Columbia, Canada.

Sample: We assembled a population-based cohort of incident SLE: those with a new diagnosis of SLE from at least one hospitalisation or rheumatologist visit, or two non-rheumatologist visits, between Jan 2001 and Dec 2010, and no prior SLE diagnosis between Jan 1990 and Dec 2000.  For each SLE case, we matched up to 5 non-SLE from the general population on age (±2 years), sex and calendar year of diagnosis.  All persons had ≥ 5 years’ follow-up in the databases before index date (first SLE-coded encounter; random date for non-SLE). 

Cost Calculation: Outpatient and prescription costs were summed directly from billing data. Case-mix methodology was used for hospitalisations.

Analysis:

We estimated the unadjusted incremental costs of SLE (difference in per-person costs between SLE and non-SLE) for the five pre-diagnosis/pre-index years (Y-5 to Y-1) and index year (Y0). 

Generalised linear models were used to further adjust for socioeconomic status (SES), urban/rural and comorbidities between SLE and non-SLE, and evaluate the impact of sex on costs.

Results:

We included 3,632 incident SLE (86% female, mean age 49.6 years) and 18,152 non-SLE.  Index-year (Y0) costs for SLE averaged $12,019 per-person (2013 CDN): 59% from hospitalisations, 24% outpatient, and 18% medications.  Costs increased by 35% per year, on average, with the biggest increases in the two years before diagnosis (see Table).  Adjusted cost ratios between SLE and non-SLE rose from 1.7 in Year -3 (Y-3) to 1.9 (Y-2), 2.4 (Y-1), and 4.0 in Y0. 

Among non-SLE, adjusted costs were higher for females than males, but among SLE, males had higher costs, controlling for age, SES and previous year’s comorbidity score.  SLE males had higher odds of hospitalisation than SLE females in Y-1 (OR=1.44, 95% CI=1.18-1.76), while non-SLE males had 15% lower odds. In Years -2 & -1, encounters with primary diagnosis of diabetes, or renal or cardiovascular disease accounted for 11% of costs for SLE males, vs. 5% for SLE females.

Adjusted M/F cost ratios in SLE were 1.15 (95% CI 1.03-1.29) in Y-2, 1.22 (1.11-1.35) in Y-1, and 1.44 (1.29-1.61) in Y0.  When comparing costs of SLE and non-SLE, the Male*SLE interaction term was significant in all years.

Conclusion:

The incremental costs of SLE are considerable, even in the years prior to diagnosis.  Unlike the general population, SLE males had higher costs than females, potentially from early comorbidities. 

Table: Unadjusted Annual Mean Per-Person Costs for SLE and matched non-SLE, before and after SLE Diagnosis/Index Date (95% Confidence Interval)

N

Mean (SD) Age

Mean (SD) Baseline Charlson-Romano Comorbidity Score

Year Before SLE Diagnosis

Year -5

Year -4

Year -3

Year -2

Year -1

Year 0

(index year)

All SLE

3,632

49.6 (15.9)

0.42 (0.49)

$3,073

($2,872 -$3,273)

$3,416

($3,190-$3,641)

$3,682

($3,414-$3,951)

$4,409

($4,100-$4,719)

$6,111

($5,741-$6,481)

$12,019

($11,150-$12,888)

All Non-SLE

18,152

49.8 (15.4)

0.14 (0.35)

$1,709

($1,645-$1,772)

$1,872

($1,812-$1,932)

$1,932

($1,868-$1,995)

$2,113

($2,033-$2,193)

$2,274

($2,167-$2,381)

$2,447

($2,345-$2,549)

Cost difference

–

–

–

$1,364

$1,544

$1,750

$2,296

$3,837

$9,572

SLE Females

3,111

49.1 (15.6)

0.40 (0.49)

$3,042

($2,826-$3,257)

$3,310

($3,098-$3,521)

$3,555

($3,283-$3,828)

$4,257

($3,949-$4,565)

$5,869

($5,484-$6,254)

$10,945

($10,153-$11,736)

Non-SLE Females

15,547

49.2 (15.1)

0.13 (0.34)

$1,746

($1,677-$1,815)

$1,875

($1,812-$1,939)

$1,944

($1,880-$2,009)

$2,110

($2,024-$2,196)

$2,268

($2,148-$2,388)

$2,436

 

($2,326-$2,546)

Cost difference

–

–

–

$1,296

$1,434

$1,611

$2,147

$3,601

$8,508

SLE Males

521

52.9 (17.1)

0.50 (0.50)

$3,258

($2,710-$3,806)

$4,047

($3,109-$4,986)

$4,440

($3,513-$5,367)

$5,321

($4,193-$6,449)

$7,557

($6,393-$8,720)

$18,433

($14,682-$22,185)

Non-SLE Males

2,605

53.0 (17.0)

0.17 (0.37)

$1,485

 

($1,328-$1,641)

$1,852

 

($1,666-$2,039)

$1,857

 

($1,643-$2,071)

$2,133

 ($1,925-$2,341)

$2,312

 

($2,101-$2,523)

$2,512

($2,239-$2,785)

Cost difference

–

–

–

$1,773

$2,195

$2,583

$3,188

$5,245

$15,921


Disclosure: N. McCormick, None; C. Marra, None; J. A. Avina-Zubieta, None.

To cite this abstract in AMA style:

McCormick N, Marra C, Avina-Zubieta JA. Incremental Direct Medical Costs of Systemic Lupus Erythematosus Patients in the Years Preceding Diagnosis and the Impact of Sex: A General Population-Based Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/incremental-direct-medical-costs-of-systemic-lupus-erythematosus-patients-in-the-years-preceding-diagnosis-and-the-impact-of-sex-a-general-population-based-study/. Accessed January 25, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incremental-direct-medical-costs-of-systemic-lupus-erythematosus-patients-in-the-years-preceding-diagnosis-and-the-impact-of-sex-a-general-population-based-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.